Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice

• Published in: Molecular therapy. Methods & clinical development Vol. 29; pp. 439 - 449
• Main Authors: Kida, Sachiho, Koshimura, Yuri, Yoden, Eiji, Yoshioka, Aya, Morimoto, Hideto, Imakiire, Atsushi, Tanaka, Noboru, Tanaka, Satowa, Mori, Ayaka, Ito, Jun, Inoue, Asuka, Yamamoto, Ryuji, Minami, Kohtaro, Hirato, Tohru, Takahashi, Kenichi, Sonoda, Hiroyuki
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 08.06.2023; American Society of Gene & Cell Therapy; Elsevier
• Subjects: blood-brain barrier; enzyme-replacement therapy; heparan sulfate; lysosomal storage disease; mucopolysaccharidosis I; Original; blood-brain barrier; mucopolysaccharidosis I; heparan sulfate; lysosomal storage disease; enzyme-replacement therapy
• ISSN: 2329-0501; 2329-0501
• DOI: 10.1016/j.omtm.2023.05.010

Mucopolysaccharidosis I (MPS I), a lysosomal storage disease caused by dysfunction of α-L-iduronidase (IDUA), is characterized by the deposition of dermatan sulfate (DS) and heparan sulfate (HS) throughout the body, which causes several somatic and central nervous symptoms. Although enzyme-replacement therapy (ERT) is currently available to treat MPS I, it does not alleviate central nervous disorders, as it cannot penetrate the blood-brain barrier. Here we evaluate the brain delivery, efficacy, and safety of JR-171, a fusion protein comprising humanized anti-human transferrin receptor antibody Fab and IDUA, using monkeys and MPS I mice. Intravenously administered JR-171 was distributed in major organs, including the brain, and reduced DS and HS concentrations in the central nervous system and peripheral tissues. JR-171 exerted similar effects on peripheral disorders similar to conventional ERT and further reversed brain pathology in MPS I mice. We found that JR-171 improved spatial learning ability, which was seen to deteriorate in the vehicle-treated mice. Further, no safety concerns were noted in repeat-dose toxicity studies in monkeys. This study provides nonclinical evidence that JR-171 might potentially prevent and even improve disease conditions in patients with neuronopathic MPS I without serious safety concerns. [Display omitted] Sonoda and colleagues confirmed the nonclinical proof-of-concept that transferrin receptor-targeting technology enables brain delivery of enzymes for treating mucopolysaccharidosis type I. The antibody fusion enzyme reduced substrate accumulation and ameliorated brain pathology in the disease model mice. These results, along with nonclinical safety assessment, support conducting clinical trials.